Having -c(=x)-, Wherein X Is Chalcogen, Bonded Directly To Carbon Of The Hetero Ring Of The Quinoline Ring System Patents (Class 514/253.08)
-
Publication number: 20130158044Abstract: The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.Type: ApplicationFiled: November 28, 2012Publication date: June 20, 2013Applicant: Otsuka Pharmaceutical Co., Ltd.Inventor: Otsuka Pharmaceutical Co., Ltd.
-
Publication number: 20130156816Abstract: The invention features compositions, methods, and kits for the administration of an oxidatively transformed carotenoid, or a fractionated component thereof, for use in aquaculture.Type: ApplicationFiled: February 18, 2011Publication date: June 20, 2013Applicant: Chemaphor Inc.Inventors: Larry Arthur Stobbs, James Gary Nickerson, Clayton Paul Dick
-
Publication number: 20130149379Abstract: Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an extended release basis, to the stomach, duodenum and upper regions of the small intestine, with drug delivery in the lower gastrointestinal tract and colon substantially restricted. The dosage form comprises a matrix of a biocompatible, hydrophilic, erodible polymer with an active agent incorporated therein, wherein the polymer is one that both swells in the presence of water and gradually erodes over a time period of hours, with swelling and erosion commencing upon contact with gastric fluid, and drug release rate primarily controlled by erosion rate.Type: ApplicationFiled: November 21, 2012Publication date: June 13, 2013Applicant: Depomed, Inc.Inventor: Depomed, Inc.
-
Publication number: 20130150311Abstract: In one aspect, the present invention is directed to a dry, flowable and compressible composition, useful as a pharmaceutical excipient, which composition comprises a mixture of hydrophobic and hydrophilic poly(ethylene oxide)-polypropylene oxide)-poly(ethylene oxide) block copolymers, and which possesses a Carr index of less than about 20. In other aspects, the present invention is directed a pharmaceutical composition comprising such adjuvant and a pharmaceutically active ingredient; as well as to a method of making the compositions.Type: ApplicationFiled: December 13, 2011Publication date: June 13, 2013Inventors: Grzegorz Pietrzynski, Valery Alakhov, Kishore Patel
-
Publication number: 20130143856Abstract: The present invention relates to a novel antibiotic, and more specifically relates to an antibiotic composition comprising flufenamic acid as an active ingredient, which can reduce drug toxicity and side effects and the problem of antibiotic resistance caused by excessive use of antibiotics since the composition exhibits a good therapeutic effect, even in a small dose, when it is administered either alone or together with another antibiotic of the prior art.Type: ApplicationFiled: January 21, 2011Publication date: June 6, 2013Applicant: SUNGKYUNKWAN UNIVERSITY FOUNDATION FORCORPORATE COLLABORATIONInventors: Kyeong Kyu Kim, Sung Wook Kang
-
Publication number: 20130116210Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).Type: ApplicationFiled: October 4, 2012Publication date: May 9, 2013Applicants: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: The Regents of the University of California, Otonomy, Inc.
-
Publication number: 20130115300Abstract: Disclosed herein is a process for preparation of taste masked dry syrup composition of ciprofloxacin comprising Ciprofloxacin taste masked granules along with at least one pharmaceutically acceptable excipient. The present invention also discloses a stable taste masked dry syrup composition of ciprofloxacin.Type: ApplicationFiled: June 3, 2010Publication date: May 9, 2013Inventor: Uma Rajan Javeri
-
Patent number: 8435565Abstract: A bioerodible composition for delivery of a bioactive agent is the reaction product of a reaction mixture which includes an oxidized dextran solution, and a mixture of solids containing a dihydrazide, a bioactive agent, and optionally a pH adjusting agent in an amount sufficient to achieve a pH of the reaction mixture of 6 or less. The composition may include a release agent for the controlled release of the bioactive agent from the composition. The composition may be administered to a body site in need of the same by providing a first aliquot portion of a reaction mixture which includes the reactants and a bioactive agent. A kit which includes a double syringe respectively containing the first and second aliquot portions of the reaction mixture may be provided so that the same may be mixed just prior to use.Type: GrantFiled: September 8, 2011Date of Patent: May 7, 2013Assignee: Royer Biomedical, Inc.Inventor: Garfield P. Royer
-
Publication number: 20130108648Abstract: The present technology provides a nanoparticulate in-situ gelling vitreous substitute, which is a liquid at room temperature to aid easy administration, such as e.g. through a small needle incision, and forms a gel within the eye, which is hydrophilic in nature, similar to the natural vitreous. The vitreous substitute formulation may include a water-soluble natural or synthetic polymer and a gelling-agent which are blended together in the presence of a cross linker, to form a gel having the properties of the vitreous humor. The process of cross linking and gelation may occur in-situ. This can be achieved by dispensing to the eye, different components of the vitreous substitute in liquid state, along with the cross linking agent.Type: ApplicationFiled: December 21, 2012Publication date: May 2, 2013Applicant: Indian Institute of Technology BombayInventor: Indian Institute of Technology Bombay
-
Patent number: 8414915Abstract: Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.Type: GrantFiled: July 13, 2012Date of Patent: April 9, 2013Assignee: Aradigm CorporationInventors: David C. Cipolla, James Blanchard
-
Publication number: 20130079353Abstract: The present invention relates to a pharmaceutical composition comprising at least one compound of formula (I) wherein R1 denotes e.g. hydrogen or straight chain C1-C6-alkyl, R2 and R3 denote e.g. hydrogen or straight chain C1-C6-alkyl, or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient for use as a medicament for the treatment of inflammatory diseases or conditions, in particular T-cell mediated inflammatory diseases or conditions.Type: ApplicationFiled: December 20, 2010Publication date: March 28, 2013Inventors: Karsten Gülow, Marcin M. Kaminski, H. Peter Krammer
-
Publication number: 20130064772Abstract: Provided are wound caring compositions and devices containing a pH-sensitive, preferably acid degradable, components contained in a water-permeable and hydronium ion permeable material. The pH-sensitive component encloses an antibiotic which is released to the wound upon infection by a microorganism at the wound site, and/or encloses a pH indicator. The antibiotic release is triggered by the microorganism's production of CO2 at the wound site which forms carbonic acid, lowers the pH at the pH sensitive components, and thus results in rupture of the liposome.Type: ApplicationFiled: September 7, 2012Publication date: March 14, 2013Inventors: Gerald F. Swiss, Stefan Schwabe, Robert M. Moriarty
-
Publication number: 20130064892Abstract: A method of making a pharmaceutical tablet comprises (a) combining (i) an aqueous networked cellulose gel with (ii) filler and (iii) an active agent to form a mixture thereof; (b) casting the mixture to form a wet tablet; (c) drying the wet tablet to form a dry pharmaceutical tablet; and then (d) optionally coating the tablet (e.g., with an enteric coating). Pharmaceutical tablets produced by such methods are also described.Type: ApplicationFiled: September 8, 2011Publication date: March 14, 2013Inventors: Raed Hashaikeh, Hatem M.N. Abushammala
-
Publication number: 20130045238Abstract: The present invention generally relates to transdermal delivery and, in particular, to transdermal delivery using nanoemulsions and other emulsions. In one aspect, the present invention is directed to emulsions comprising a first, continuous phase and a second, discontinuous phase. The first phase may be an aqueous liquid and the second phase may comprise a lipid, such as isopropyl myristate. In some cases, a surfactant, such as Pluronic® L61, is used to stabilize the emulsion. Surprisingly, it has been found that such emulsions are effective at delivering pharmaceutically active agents, such as ciprofloxacin, when the formulation has a very low water content, for example, less than 30 wt % or less than 10 wt %. This is surprising because high water contents—not low water contents—are typically correlated with greater transdermal drug delivery, and thus, a low water content would have been considered to be unfavorable for facilitating transdermal drug delivery.Type: ApplicationFiled: April 22, 2010Publication date: February 21, 2013Applicant: Agency for Science, Technology and ResearchInventors: Edwin Pei Yong Chow, Jackie Y. Ying, Shu Jun Gao
-
Publication number: 20130040960Abstract: An ophthalmic gel of gatifloxacin and the preparation method thereof are disclosed. The gel comprises gatifloxacin or its pharmaceutical salts, matrix and water. Said matrix is one or more selected from carbomer, mixture of carbomer and HPMC, and sodium hyaluronate.Type: ApplicationFiled: November 23, 2010Publication date: February 14, 2013Applicant: SHENYANG XINGQI PHARMACEUTICAL CO., LTD.Inventors: Jidong Liu, Yuchun Yang, Hai Tang
-
Publication number: 20130039904Abstract: The present invention discloses a gamboge acid cyclization analogs, their preparation methods and applications by semi-synthesis with the following structural formula I-III: Where ring A, ring B or/and ring C is 4-10 membered saturated or/and unsaturated aliphatic ring aliphatic heterocycle or aryl heterocycle. R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 or/and R12 is, independently at each occurrence, optionally substituted substituent of glycosyl, multi-hydroxyl, amino acid, acyloxy, phosphoric acid oxy, sulfonyloxy, alkoxy, aryloxy, heterocyclic oxy, thiol, aliphatic or cyclic group containing oxygen, sulfur, nitrogen or phosphorus, one of the substituents or combinations thereof. The present invention has antitumor activity management, antiviral, antibacterial and antifungal activity management, as anti-tumor, anti-viral, immune, antibacterial and antifungal agents, with other known anti-tumor, anti-viral, immune, together with the application of antibacterial and antifungal.Type: ApplicationFiled: August 2, 2010Publication date: February 14, 2013Applicant: Liaoning Lifeng Scientific & Technology Development Company Ltd.Inventor: Lifeng Xu
-
Publication number: 20130035327Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.Type: ApplicationFiled: October 8, 2012Publication date: February 7, 2013Inventors: Sara Hadida-Ruah, Anna Hazlewood, Peter Grootenhuis, Fredrick Van Goor, Ashvani Singh, Jinglan Zhou, Jason McCartney
-
Publication number: 20130029918Abstract: The present invention provides compositions for delivering highly water-soluble drugs (such as vinca alkaloids) and methods of using such compositions.Type: ApplicationFiled: June 21, 2012Publication date: January 31, 2013Applicant: Adventrx Pharmaceuticals, Inc.Inventor: Andrew Xian Chen
-
Publication number: 20130023540Abstract: The invention relates to the simplified treatment of mastitis with enrofloxacin or ciprofloxacin, in particular in the case of cows.Type: ApplicationFiled: September 21, 2012Publication date: January 24, 2013Applicant: BAYER HEALTHCARE AGInventor: Bayer HealthCare AG
-
Publication number: 20130022661Abstract: A bio-remodable augmentation device including an implantable member configured for maintaining space in a bone defect. The implantable member is formed from a bio-remodable composite having structural properties so as to aid in the generation of new bone tissue and eventually be reabsorbed in the newly formed bone tissue. This structural and bio-remodable implant reduces, if not eliminates, the need to remove the implantable member from the patient once new bone tissue is formed. A kit including the implantable devices and bone growth material is disclosed. Methods of use are also disclosed.Type: ApplicationFiled: July 21, 2011Publication date: January 24, 2013Applicant: Warsaw Orthopedic, Inc.Inventor: William F. McKay
-
Patent number: 8343964Abstract: The invention relates to the use of at least one compound of the formula (I), in which R and R3 are particularly a hydrogen atom, R1 is particularly a hydrogen atom or a methyl, ethyl or isobutyl mi group, R4, R5, R6 and R7 are independently a hydrogen atony, an alkoxyl group with 1 to 7 carbon atoms or a halogen atom, R2 is a hydrogen atom, an O? group or an OH group, B is an N-GP1 or NRc, group, GP1 being a Boc or Cbz group, and Rc is a hydrogen atom or a methyl or t-butyl group, for preparing a drug for treating conditions associated with bacterial infections, in particular for treating bacterial diseases.Type: GrantFiled: January 31, 2008Date of Patent: January 1, 2013Assignees: Universite Joseph Fourier, Centre National de la Recherche ScientifiqueInventors: Jean-Noel Marie Leon Denis, Xavier Jean Georges Marie Guinchard, Nicole Jeanne Moreau born Laffont, Luc Neuville, Yannick Vallee
-
Publication number: 20120328671Abstract: The invention relates to products comprising an antibiotic agent and a second agent being a dispersant or an anti-adhesive agent, in particular a mucolytic dispersant or a mucolytic anti-adhesive agent, which are useful in relation to the prevention and treatment of bacterial infections.Type: ApplicationFiled: June 1, 2012Publication date: December 27, 2012Applicant: NOVABIOTICS LIMITEDInventors: Deborah O'Neil, Cedric Charrier
-
Publication number: 20120316124Abstract: The present invention relates to compounds formula (I), wherein P is P1, P2, heterocyclyl or heterocyclyl substituted by one to five Z; and wherein A1, A2, A3, A4, G1, R1, R2, R3, R4, R5, R6, R17, R18, R19 and R20 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, nematicidal and molluscicidal compositions comprising the compounds of formula (I) and to methods of using the compounds of formula (I) to control insect, acarine, nematode and mollusc pests.Type: ApplicationFiled: February 17, 2011Publication date: December 13, 2012Applicant: SYNGENTA CROP PROTECTION LLCInventors: Thomas Pitterna, Myriem El Qacemi, Jerome Yves Cassayre, Peter Renold, Vladimir Bobosik
-
Publication number: 20120301422Abstract: The invention provides a method of enhancing the action of a pharmaceutical agent selected from the group consisting of the anti-infective agents, the group comprising of the antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, and from the group consisting of the CPNS agents selected from the group of compounds acting on the central or peripheral nervous system, but excluding coal tar solution and H1-antagonist antihistamines and also excluding anti-inflammatory, analgesic and antipyretic agents and also provides an enhanced method for the administration of a nucleic acid substance to the cells of an animal, a plant or a micro-organism.Type: ApplicationFiled: January 16, 2003Publication date: November 29, 2012Inventor: Petrus Johannes Meyer
-
Publication number: 20120302582Abstract: This invention relates to novel cancer treatment compositions and associated therapeutic methods. More particularly, this invention relates in part to small chemical bifunctional inhibitors of DNA replication and repair proteins Metnase and/or Intnase (also termed Gypsy Integrase, Gypsy Integrease-1, Gypsy Retransposon Integrase 1, or GIN-I) that simultaneously damage DNA, and to a therapeutic method that utilizes the inhibitors to increase the effectiveness of cancer treatment protocols, including radiation therapy. In preferred embodiments, compounds, compositions and methods of treatment of the invention are used to treat a patient suffering from leukemia (e.g. acute myeloid leukemia (AML) and related cancers.Type: ApplicationFiled: January 26, 2011Publication date: November 29, 2012Inventors: Robert Hromas, Andrei Leitao, Tudor I. Oprea, Larry A. Sklar, Elizabeth A. Williamson, Justin Wray, Wei Wang
-
Publication number: 20120289470Abstract: The invention includes compositions for transmucosal administration to an animal comprising at least one active agent and a pharmaceutically acceptable carrier. A preferred active agent is selected from the group consisting of meloxicam, carprofen, enrofloxacin, clemastine, diphenhydramine, digoxin, levothyroxine, cyclosporine, ondansetron, lysine, zolpidem, propofol, nitenpyram, ivermectin, milbemycin, and pharmaceutically acceptable salts, solvates and esters thereof. In another embodiment, the invention includes methods of treating or preventing a condition in an animal comprising transmucosally administering a composition comprising a therapeutically or prophylactically effective amount of an active agent and a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 15, 2011Publication date: November 15, 2012Inventors: Mark C. HEIT, Antonio M. BENITZ, Dennis F. STEADMAN, David M. PETRICK
-
Publication number: 20120282328Abstract: Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.Type: ApplicationFiled: July 13, 2012Publication date: November 8, 2012Inventors: DAVID C. CIPOLLA, JAMES BLANCHARD
-
Publication number: 20120251464Abstract: Compounds are described that are effective in enhancing the efficacy of antimicrobial agents. Also described are methods of using such compounds and compositions that include such compounds. The composition includes a chalcone compound and, optionally, an antimicrobial agent.Type: ApplicationFiled: December 18, 2009Publication date: October 4, 2012Applicants: Indian Institute of Integrative Medicine, Colgate-Palmolive ComplanyInventors: Ravi Subramanyam, Laurence Du-Thumm, Ghulam Nabi Qazi, Inshad Ali Khan, Krishan Avtar Suri, Naresh Kumar Satti, Furqan Ali, Nitin Pal Kalia
-
Publication number: 20120252720Abstract: The present invention relates to compositions and methods useful for the treatment of ear disorders, administered to a treated ear in the form of a foam or a mousse. Administering a medicament in such forms will increase the residence time of the medicament in the ear canal, provide relatively uniform distribution of the composition, and can increase the penetration of the active pharmaceutical ingredient in the affected area, may release active substances slowly, enhance treatment effectiveness, increase compliance and is more convenient to use than currently available ear medications. The administration in the form of a foam or a mousse may preferably be provided as a metered dose, of a volume suitable to fill the ear canal.Type: ApplicationFiled: April 2, 2012Publication date: October 4, 2012Applicant: Otic Pharma Ltd.Inventor: Eran Eilat
-
Publication number: 20120244206Abstract: Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.Type: ApplicationFiled: October 22, 2007Publication date: September 27, 2012Inventors: David C. Cipolla, James Blanchard
-
Publication number: 20120238517Abstract: The present invention relates to compounds of formula (I): Wherein A1, A2, A3, A4, G1, L, Y1, Y2, Y3, Y4, R1, R2, R3 and R4 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to intermediates for preparing compounds of formula (I), to compositions comprising them and to methods of using them to combat and control insect, acarine, nematode and mollusc pests.Type: ApplicationFiled: December 1, 2010Publication date: September 20, 2012Applicant: SYNGENTA CROP PROTECTION LLCInventors: Jerome Yves Cassayre, Peter Renold, Myriem El Qacemi, Thomas Pitterna, Julie Clementine Toueg
-
Publication number: 20120213772Abstract: The invention provides for a method for identifying a biomarker in a fecal sample of a subject in need of such identification comprising: determining whether a fecal sample collected from a subject comprises a biomarker.Type: ApplicationFiled: January 13, 2012Publication date: August 23, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Janet R. Jansson, Benjamin Willing, Phillippe Schmitt-Kopplin, Agnes Fekete, Marianna Lucio
-
Publication number: 20120213825Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there is a delayed release dosage form, as well as two or more delayed sustained release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: ApplicationFiled: October 18, 2011Publication date: August 23, 2012Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
-
Publication number: 20120207822Abstract: Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with 3,3-dimethyl-1-butanol (DMB) and related compounds, and pharmaceutical formulations thereof. In other embodiments, the present invention provides methods of administering a gut flora targeting antibiotic to a subject prior to a procedure that is associated with a risk of causing thrombosis, heart-attack, and/or platelet hyper-responsiveness.Type: ApplicationFiled: February 1, 2012Publication date: August 16, 2012Inventors: Stanley Hazen, Zeneng Wang
-
Publication number: 20120202694Abstract: The present invention relates to methods for producing particles of a biologically active material using dry milling processes as well as compositions comprising such materials, medicaments produced using said biologically active materials in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of said biologically active materials administered by way of said medicaments.Type: ApplicationFiled: April 23, 2010Publication date: August 9, 2012Inventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H William Bosch
-
Patent number: 8231903Abstract: The invention relates to a system for controlled release of medicinally active substances, which comprises sucrose acetate isobutyrate (SAIB) and a further solvent.Type: GrantFiled: September 12, 2005Date of Patent: July 31, 2012Assignee: Bayer Animal Health GmbHInventors: Kristine Fraatz, Dirk Mertin, Iris Heep
-
Publication number: 20120172371Abstract: A method for treating cancer in a subject, comprising administering to a subject having cancer a therapeutically effective amount of (i) a fluoroquinolone derivative that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity or (ii) a sulfonamide moiety-containing compound that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity, thereby treating the cancer in the subject. In certain embodiments, the fluoroquinolone derivative or sulfonamide moiety-containing compound is co-administered with a topoisomerase I (TopI) inhibitor.Type: ApplicationFiled: October 27, 2011Publication date: July 5, 2012Inventors: Yves Pommier, Christophe Marchand, Periyasamy Selvam, Thomas Dexheimer, Kasthuraiah Maddali
-
Publication number: 20120157397Abstract: The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.Type: ApplicationFiled: November 28, 2011Publication date: June 21, 2012Inventors: Stanley L. Hazen, Zeneng Wang, Bruce S. Levison
-
Publication number: 20120141574Abstract: A palatable, edible soft chewable medication vehicle for delivery of a pharmaceutically acceptable active ingredient, such as a drug, to an animal or human subject. The edible soft chews contain only food grade or better inactive ingredients, and preferably do not contain ingredients of animal origin. Processes for manufacturing the edible soft chews do not require the use of heat or the addition of water during mixing of active and inactive ingredients, provide stable concentrations of the active ingredient, and produce chews of consistent weight and texture.Type: ApplicationFiled: February 14, 2012Publication date: June 7, 2012Inventors: Neil E. Paulsen, Roland Johnson, Michael Coffee
-
Publication number: 20120141491Abstract: The subject application provides small compounds that are able to increase/enhance autophagy in various cells. These compounds are useful in augmenting existing treatments of various cancers, microbial/viral infections, and neurodegenerative diseases. Thus, the subject application also provides methods of treating various types of cancers, microbial/viral infections, and neurodegenerative diseases.Type: ApplicationFiled: August 9, 2010Publication date: June 7, 2012Applicant: University of Florida Research Foundation Inc.Inventors: William A. Dunn, Debra Everton Akin, Brian Keith Law
-
Publication number: 20120142635Abstract: The present invention relates to compounds of the Formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria:Type: ApplicationFiled: February 8, 2012Publication date: June 7, 2012Applicant: Morphochem Aktiengesellschaft Fur Kombinatorische ChemieInventors: Christian Hubschwerlen, Jean-Luc Specklin, Daniel Baeschlin, Christine Schmitt, Stefan Müller, Michael W. Cappi
-
Patent number: 8183236Abstract: Pharmacophore models to be used in drug design and discovery are provided. An in silico protocol and in vitro assays are presented. Compounds and their pharmaceutically acceptable salts with HIV-1 integrase inhibitory and anti-HIV activity and use thereof in the treatment of HIV/AIDS and related infections either alone or in combination with all the known antiretroviral therapeutics are described.Type: GrantFiled: April 14, 2008Date of Patent: May 22, 2012Assignee: University of Southern CaliforniaInventors: Nouri Neamati, Raveendra S. Dayam
-
Publication number: 20120093759Abstract: Medical devices, wound dressings, and methods of dressing wounds are described. Devices and methods using silicone and pharmaceutically active agents are described. Devices including covers and bases are described.Type: ApplicationFiled: November 17, 2011Publication date: April 19, 2012Inventor: David J. Vachon
-
Publication number: 20120082730Abstract: The present technology provides a nanoparticulate in-situ gelling vitreous substitute, which is a liquid at room temperature to aid easy administration, such as e.g. through a small needle incision, and forms a gel within the eye, which is hydrophilic in nature, similar to the natural vitreous. The vitreous substitute formulation may include a water-soluble natural or synthetic polymer and a gelling-agent which are blended together in the presence of a cross linker, to form a gel having the properties of the vitreous humor. The process of cross linking and gelation may occur in-situ. This can be achieved by dispensing to the eye, different components of the vitreous substitute in liquid state, along with the cross linking agent.Type: ApplicationFiled: September 30, 2010Publication date: April 5, 2012Inventors: Rinti Banerjee, Edmund Carvalho
-
Publication number: 20120070467Abstract: The present invention includes and provides a method of delivering a medicament to an eye of a subject in need thereof a solution, the method comprising: (a) providing droplets containing the medicament with a specified average size and average initial ejecting velocity; and (b) delivering the medicament to the eye, where the droplets deliver a percentage of the ejected mass of the droplets to the eye.Type: ApplicationFiled: July 15, 2011Publication date: March 22, 2012Applicant: Corinthian Ophthalmic, Inc.Inventors: Bernard L. Ballou, JR., Mark Packer, Russell John Mumper, Tsontcho Inachulev
-
Publication number: 20120071430Abstract: Bacterial quorum-sensing molecule analogs having the following structures: and methods of reducing bacterial pathogenicity, comprising providing a biological system comprising pathogenic bacteria which produce natural quorum-sensing molecule; providing a synthetic bacterial quorum-sensing molecule having the above structures and introducing the synthetic quorum-sensing molecule into the biological system comprising pathogenic bacteria. Further is provided a method of targeted delivery of an antibiotic, comprising providing a synthetic quorum-sensing molecule; chemically linking the synthetic quorum-sensing molecule to an antibiotic to produce a quorum-sensing molecule-antibiotic conjugate; and introducing the conjugate into a biological system comprising pathogenic bacteria susceptible to the antibiotic.Type: ApplicationFiled: November 1, 2011Publication date: March 22, 2012Applicant: Los Alamos National LaboratoryInventors: Rashi Iyer, Kumkum Ganguly, Louis A. Silks
-
Publication number: 20120046246Abstract: This invention relates to therapeutic methods for treating or preventing an osteoclast-related disease or disorder in a subject identified as in need of a treatment of bone diseases, compounds for such uses, and compositions thereof.Type: ApplicationFiled: December 18, 2009Publication date: February 23, 2012Applicant: University of Florida Research FoundationInventors: Lexie Shannon Holliday, David A. Ostrov
-
Publication number: 20120035121Abstract: An antibiotic product is comprised of at least two dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as one or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: ApplicationFiled: October 14, 2011Publication date: February 9, 2012Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, JR., Sandra E. Wassink
-
Publication number: 20120010215Abstract: The invention relates to inhalable quinolonecarboxylic acid derivative compositions for local control of diseases of the respiratory organs, in particular of lung diseases.Type: ApplicationFiled: July 28, 2011Publication date: January 12, 2012Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Rainer Endermann, Harald Labischinski, Christoph Ladel, Uwe Petersen, Ben Newton
-
Publication number: 20110318416Abstract: A bioerodible composition for delivery of a bioactive agent is the reaction product of a reaction mixture which includes an oxidized dextran solution, and a mixture of solids containing a dihydrazide, a bioactive agent, and optionally a pH adjusting agent in an amount sufficient to achieve a pH of the reaction mixture of 6 or less. The composition may include a release agent for the controlled release of the bioactive agent from the composition.Type: ApplicationFiled: September 8, 2011Publication date: December 29, 2011Applicant: ROYER BIOMEDICAL, INC.Inventor: Garfield P. ROYER